Financial Performance and Subsidiaries Revenue
API FACILITES
NATCO
Strategically important business - develops APIs primarily for third party sales and also for captive consumption
Portfolio of 44 (1) active US DMFS with niche products under development
Focus on complex oncology molecules. Other therapeutic areas of development includes CNS and Orphan indications
Exports are focused on the US, EU, Latin America and RoW markets.
In-house KSMs for several APIs a key competitive advantage
MEKAGUDA
TELANGANA
Oncology API's and speciality
products
Approvals from USFDA, PMDA
(Japan), COFEPRIS (Mexico),
EDQM (Europe), ANVISA,
WHO, EU GMP (Germany),
CDSCO
STRENGTHS
Last USFDA audit successfully
completed and EIR received in
September 2019
Complex multi-step synthesis & scale-up
Advanced synthetic/separation technologies
Containment facility for handling High potency APIs
Peptide (Solid phase) pharmaceuticals
Oligo nucleotide Pharmaceuticals
Well established process safety engineering lab
CHENNAI
TAMIL NADU
Dedicated for Oncology
USFDA, CDSCO, WHO-GMP
USFDA audit with Establishment
Inspection Report (EIR) received in
July 2019
(1)
As of June 30, 2023
9View entire presentation